For Pharmaceutical and Life Sciences

Protecting Scientific Judgement in Pharma: Using AI Without Losing Your Edge

Your researchers increasingly rely on AI models to predict molecular behaviour, optimise trial designs, and generate regulatory analysis. The risk is real: when a chemist uses Schrödinger AI every day without understanding the physics underneath, their ability to spot where the model fails disappears. Your competitive advantage comes from people who can question the AI, not people who trust it.

These are suggestions. Your situation will differ. Use what is useful.

Download printable PDF

Maintain the Scientific Skill That AI Cannot Replace

Drug discovery teams using BenevolentAI or Insilico Medicine must still build foundational knowledge in the chemistry and biology they work with. A researcher who cannot read a binding affinity prediction and immediately sense whether it makes sense has outsourced their judgement. Set expectations that AI tools augment wet lab intuition, not replace it. Your best scientists should be able to reject an AI recommendation and explain why in terms that stand up in a regulatory meeting.

›Require researchers to document their reasoning before and after checking an AI prediction. If the reasons are the same, someone is not thinking critically.
›Run quarterly check-ins where teams present a case where they disagreed with an AI tool and why they were right. This keeps scepticism alive.
›Pair junior chemists with senior mentors who can still solve problems without reaching for ChatGPT. Apprenticeship matters more when AI is everywhere.

Interrogate AI-Driven Clinical Trial Design Before It Reaches Patients

When you use AI to optimise trial protocols, inclusion criteria, or endpoint selection, you compress months of expert discussion into minutes. This speed is valuable. But if your team cannot explain why an AI-selected primary endpoint actually matters to patients, your trial will fail or mislead. Regulators like the EMA are watching whether trial designs reflect genuine patient need or just algorithmic convenience. Make patient relevance a gate that AI recommendations must pass, not an afterthought.

›Before locking in an AI-optimised trial design, run it past at least one experienced clinical investigator who designed trials before AI existed. They will spot gaps.
›Require your medical team to write a plain-language justification for each primary endpoint that does not mention the AI model. If they cannot do this, the endpoint is too machine-driven.
›Document where the AI suggested something your team rejected and why. This paper trail protects you in regulatory conversations and shows you were not passive.

Build Traceability Into Your Regulatory Submissions

Regulators cannot grade your submission if they cannot see how you arrived at your conclusions. When IBM Watson Health or similar tools generate pharmacokinetic analysis or safety summaries, your dossier becomes a black box. The FDA and EMA do not yet have standards for reviewing AI-generated evidence, which means you need to over-explain your work. Every analysis that touched an AI tool should have a human sign-off that states what the AI did, what assumptions it made, and why a human expert agrees with the result.

›Create a dossier checklist that flags every section where AI was used. Write a brief methods section for each that regulators can actually read and follow.
›For high-stakes analyses like adverse event summaries or efficacy conclusions, run the AI output past your head of safety or medical affairs before it goes into the dossier. Their initials matter.
›Keep the original AI output and your expert review side by side in your submission records. If a regulator questions a conclusion, you can show both the machine reasoning and the human reasoning.

Create a Culture of Dissent Around AI Predictions

Teams that normalise disagreement with AI stay sharper than teams that treat AI as final. In drug discovery, the moment a researcher assumes a Schrödinger prediction is correct because it came from the model, you have lost a layer of quality control. Build meetings where people are expected to push back on surprising results. Make it safe for a junior scientist to say an AI recommendation looks wrong. Organisations where scepticism is valued, not punished, catch problems early.

›In project reviews, allocate time specifically for 'challenges to the AI'. Ask the team what the model might have missed and what they would do differently based on their own expertise.
›Reward people who found errors in AI recommendations with the same recognition as people who used AI successfully. Catching mistakes is valuable work.
›When an AI prediction turns out to be wrong in the lab, treat it as a learning event for the whole team, not a failure of the tool. Use it to refine how you use that tool next time.

Preserve Decision-Making Authority in Human Hands

AI can propose a lead compound, suggest a trial population, or draft a safety conclusion. But the decision to move forward belongs to people who can be held accountable. If you automate decisions by accepting AI recommendations without meaningful human review, you have shifted responsibility away from your organisation. Regulators will hold you accountable for decisions your AI makes. Keep human experts in the loop at every gate: compound selection, trial progression, regulatory strategy. Make it clear in your governance that AI advises and humans decide.

›Designate a named individual who must formally approve any major decision that AI influenced. Their name and date go into the record. This creates accountability.
›Set thresholds where AI recommendations are automatically escalated. For example, if Insilico Medicine flags a safety concern, a toxicologist must review it, not just a data analyst.
›Run a quarterly audit of decisions made by your organisation in the past three months. Flag any where it is unclear who actually made the call and why. Use this to tighten your process.

Key principles

1.Researchers who cannot interrogate an AI model have outsourced their judgement and become a liability to your organisation.
2.Speed in drug discovery means nothing if you end up with trials that fail because the endpoints were machine-optimised rather than patient-relevant.
3.Regulators cannot evaluate what they cannot see, so every AI-generated analysis in your submission must be traceable back to human expertise and reasoning.
4.Organisations where people fear disagreeing with AI predictions lose the quality control that catches errors before they become expensive or dangerous.
5.Decision-making authority must stay with named individuals who can be held accountable, regardless of what the AI recommends.

Key reminders

Before your organisation adopts a new AI tool, ask whether your researchers can still do the work manually if the tool failed. If the answer is no, you have created a knowledge gap.
Keep a log of AI predictions that turned out to be wrong. Review it quarterly with your teams. This keeps healthy scepticism alive and helps you understand where each tool tends to fail.
In regulatory interactions, assume the reviewer has not seen your AI tool before. Explain what it does and why a human expert agrees with its output, not why the model is trustworthy.
Hire or retain at least one senior expert per therapeutic area who was trained before AI tools existed and can still design studies and analyse data without them.
When an AI tool becomes central to your workflow, schedule annual refresher training for teams on the underlying science it is predicting. Do not let the science become a black box.